<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cybin, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/cybin-inc-1</link>
    <description>Latest news and press releases for Cybin, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 11:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cybin-inc-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6a446beedb30cb6ff603f.webp</url>
      <title>Cybin, Inc.</title>
      <link>https://6ix.com/company/cybin-inc-1</link>
    </image>
    <item>
      <title>Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health&amp;#xA0;</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-partners-with-tara-mind-to-advance-veteran-mental-healthandxa0</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-partners-with-tara-mind-to-advance-veteran-mental-healthandxa0</guid>
      <pubDate>Tue, 28 Apr 2026 11:30:00 GMT</pubDate>
      <description>Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and e...</description>
    </item>
    <item>
      <title>Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-strengthens-scientific-advisory-board-with-addition-of-dr-robert-langer-and-dr-stephen-brannan</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-strengthens-scientific-advisory-board-with-addition-of-dr-robert-langer-and-dr-stephen-brannan</guid>
      <pubDate>Thu, 23 Apr 2026 11:30:00 GMT</pubDate>
      <description>Addition of globally recognized leaders in translational science and clinical development as the ...</description>
    </item>
    <item>
      <title>Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-expresses-support-for-executive-order-advancing-psychedelic-research-and-regulatory-pathways-for-serious-mental-health-conditions</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-expresses-support-for-executive-order-advancing-psychedelic-research-and-regulatory-pathways-for-serious-mental-health-conditions</guid>
      <pubDate>Mon, 20 Apr 2026 12:15:00 GMT</pubDate>
      <description>NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma&amp;#x2122;&amp;#xA0;(Nasdaq: HELP)...</description>
    </item>
    <item>
      <title>Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-strengthens-medical-leadership-by-appointing-dr-ken-kramer-as-senior-vice-president-medical-affairs</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-strengthens-medical-leadership-by-appointing-dr-ken-kramer-as-senior-vice-president-medical-affairs</guid>
      <pubDate>Thu, 16 Apr 2026 11:30:00 GMT</pubDate>
      <description>Dr. Kramer&amp;#x2019;s 25 years&amp;#x2019; of experience in neuroscience and proven track record leadin...</description>
    </item>
    <item>
      <title>Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-strengthens-executive-team-with-appointment-of-jill-conwell-as-chief-people-officer-7</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-strengthens-executive-team-with-appointment-of-jill-conwell-as-chief-people-officer-7</guid>
      <pubDate>Thu, 12 Mar 2026 11:30:00 GMT</pubDate>
      <description>Proven human resources and organizational strategist brings more than two decades of leadership a...</description>
    </item>
    <item>
      <title>CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions</title>
      <link>https://6ix.com/company/cybin-inc-1/news/cns-drug-developers-add-pharma-veterans-as-sector-nears-first-fda-decisions</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/cns-drug-developers-add-pharma-veterans-as-sector-nears-first-fda-decisions</guid>
      <pubDate>Mon, 09 Mar 2026 14:50:00 GMT</pubDate>
      <description>CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions         Canada NewsWi...</description>
    </item>
    <item>
      <title>Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion</title>
      <link>https://6ix.com/company/cybin-inc-1/news/anxiety-treatment-boom-gad-therapies-poised-for-multi-billion-dollar-expansion</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/anxiety-treatment-boom-gad-therapies-poised-for-multi-billion-dollar-expansion</guid>
      <pubDate>Thu, 05 Mar 2026 14:30:00 GMT</pubDate>
      <description>Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion         Canada Ne...</description>
    </item>
    <item>
      <title>Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-announces-topline-results-in-phase-2-signal-detection-study-for-hlp004-in-patients-with-generalized-anxiety-disorder-11</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-announces-topline-results-in-phase-2-signal-detection-study-for-hlp004-in-patients-with-generalized-anxiety-disorder-11</guid>
      <pubDate>Thu, 05 Mar 2026 12:30:00 GMT</pubDate>
      <description>Statistically significant (p&amp;lt;0.0001) and clinically meaningful improvement in Hamilton Anxiety...</description>
    </item>
    <item>
      <title>Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments</title>
      <link>https://6ix.com/company/cybin-inc-1/news/psychedelic-biotechs-push-toward-phase-3-five-companies-advancing-cns-treatments</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/psychedelic-biotechs-push-toward-phase-3-five-companies-advancing-cns-treatments</guid>
      <pubDate>Fri, 27 Feb 2026 16:44:00 GMT</pubDate>
      <description>Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments         Canada ...</description>
    </item>
    <item>
      <title>Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders</title>
      <link>https://6ix.com/company/cybin-inc-1/news/psychedelic-medicine-advances-here-are-five-companies-targeting-cns-disorders</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/psychedelic-medicine-advances-here-are-five-companies-targeting-cns-disorders</guid>
      <pubDate>Thu, 26 Feb 2026 17:07:00 GMT</pubDate>
      <description>Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders         Canada New...</description>
    </item>
    <item>
      <title>Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity</title>
      <link>https://6ix.com/company/cybin-inc-1/news/next-generation-psychiatric-therapies-target-massive-dollar40b-market-opportunity</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/next-generation-psychiatric-therapies-target-massive-dollar40b-market-opportunity</guid>
      <pubDate>Tue, 24 Feb 2026 14:35:00 GMT</pubDate>
      <description>Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity         Canada News...</description>
    </item>
    <item>
      <title>Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors &amp; Chair of the Scientific Advisory Committee</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-and-chair-of-the-scientific-advisory-committee</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-appoints-former-pfizer-chief-medical-officer-dr-freda-lewis-hall-to-board-of-directors-and-chair-of-the-scientific-advisory-committee</guid>
      <pubDate>Tue, 24 Feb 2026 12:45:00 GMT</pubDate>
      <description>In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and...</description>
    </item>
    <item>
      <title>Nature Medicine Publishes Helus Pharma&apos;s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder</title>
      <link>https://6ix.com/company/cybin-inc-1/news/nature-medicine-publishes-helus-pharmas-randomized-placebo-controlled-phase-2a-trial-of-spl026-in-major-depressive-disorder</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/nature-medicine-publishes-helus-pharmas-randomized-placebo-controlled-phase-2a-trial-of-spl026-in-major-depressive-disorder</guid>
      <pubDate>Tue, 17 Feb 2026 12:30:00 GMT</pubDate>
      <description>Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a ...</description>
    </item>
    <item>
      <title>HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-reports-third-quarter-fiscal-year-2026-financial-results-and-recent-business-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-reports-third-quarter-fiscal-year-2026-financial-results-and-recent-business-highlights</guid>
      <pubDate>Fri, 13 Feb 2026 12:31:19 GMT</pubDate>
      <description>- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter eve...</description>
    </item>
    <item>
      <title>Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market</title>
      <link>https://6ix.com/company/cybin-inc-1/news/novel-serotonergic-agonists-positioned-to-capture-share-of-dollar150b-neuropsychiatric-market</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/novel-serotonergic-agonists-positioned-to-capture-share-of-dollar150b-neuropsychiatric-market</guid>
      <pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
      <description>Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market        ...</description>
    </item>
    <item>
      <title>Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-appoints-michael-cola-as-chief-executive-officer-to-lead-next-phase-of-scale-and-execution</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-appoints-michael-cola-as-chief-executive-officer-to-lead-next-phase-of-scale-and-execution</guid>
      <pubDate>Tue, 10 Feb 2026 12:30:00 GMT</pubDate>
      <description>Former President of Shire PLC&amp;#x2019;s (&amp;#x201C;Shire&amp;#x201D;) Specialty Pharmaceutical business,...</description>
    </item>
    <item>
      <title>HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq</title>
      <link>https://6ix.com/company/cybin-inc-1/news/helus-pharma-propels-therapeutic-innovation-in-mental-health-and-commences-trading-on-nasdaq</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/helus-pharma-propels-therapeutic-innovation-in-mental-health-and-commences-trading-on-nasdaq</guid>
      <pubDate>Mon, 05 Jan 2026 12:30:00 GMT</pubDate>
      <description>Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Com...</description>
    </item>
    <item>
      <title>Cybin Initiates At-The-Market Equity Program of up to US$100 Million</title>
      <link>https://6ix.com/company/cybin-inc-1/news/cybin-initiates-at-the-market-equity-program-of-up-to-usdollar100-million-1</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/cybin-initiates-at-the-market-equity-program-of-up-to-usdollar100-million-1</guid>
      <pubDate>Tue, 30 Dec 2025 20:33:00 GMT</pubDate>
      <description>Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (&amp;#x201C;   Cybin   &amp;#x201D; or the &amp;#x201C...</description>
    </item>
    <item>
      <title>Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq</title>
      <link>https://6ix.com/company/cybin-inc-1/news/cybin-to-transfer-us-stock-exchange-listing-to-nasdaq-1</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/cybin-to-transfer-us-stock-exchange-listing-to-nasdaq-1</guid>
      <pubDate>Fri, 19 Dec 2025 23:45:00 GMT</pubDate>
      <description>Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough pharmaceutical comp...</description>
    </item>
    <item>
      <title>KILL Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq</title>
      <link>https://6ix.com/company/cybin-inc-1/news/kill-cybin-to-transfer-us-stock-exchange-listing-to-nasdaq</link>
      <guid isPermaLink="true">https://6ix.com/company/cybin-inc-1/news/kill-cybin-to-transfer-us-stock-exchange-listing-to-nasdaq</guid>
      <pubDate>Thu, 18 Dec 2025 12:30:00 GMT</pubDate>
      <description>Cybin Inc. requests that their press release NewsItemId: 20251218742920 &amp;#x201C;Cybin to Transfer...</description>
    </item>
  </channel>
</rss>